BPC-15 reduces trinitrobenzene sulfonic acid-induced colonic damage in rats.
Veljaca. M M; Lesch. C A CA; Pllana. R R; Sanchez. B B; Chan. K K; Guglietta. A A
Key Findings
- Intraperitoneal (i.p.) BPC‑15 reduced TNBS‑induced colonic necrosis in rats, with greater effect at higher doses.
- MPO activity, a sign of neutrophil‑driven inflammation, dropped alongside the tissue protection in a dose‑dependent manner.
- Direct intracolonic delivery of BPC‑15 (10 nmol/kg) did not significantly improve damage or MPO levels.
Practical Outcomes
- For biohackers interested in gut health, the study suggests that systemic (i.p.) delivery of BPC‑15 may be more effective than local application for reducing inflammation. However, the work is limited to rats, uses a non‑human route of administration, and does not provide human dosing guidance, so it offers only modest, confirmatory insight rather than a ready‑to‑use protocol.
Summary
In rats, giving BPC‑15 by an injection into the belly (intraperitoneal) before a chemical that damages the colon lowered the amount of tissue damage and the inflammation marker (MPO) in a dose‑dependent way. Giving the same amount directly into the colon didn’t help.
Abstract
The effect of BPC-15 (Booly Protection Compound-15) was evaluated in a rat model of colonic injury. A single intracolonic administration of trinitrobenzene sulfonic acid (TNBS) dissolved in ethanol induces severe colonic damage, which is characterized by areas of necrosis surrounded by areas of acute inflammation. The damage is associated with high myeloperoxidase (MPO) activity, mainly as a reflection of neutrophilic infiltration into the damaged tissue. In this study, 1 hr before a single intracolonic administration of 50 mg/kg of TNBS in 50% ethanol, the animals were treated with one of the following doses of BPC-15: 0.0001, 0.001, 0.01, 0.1, 1 or 10 nmol/kg administered i.p. or with a dose of 10 nmol/kg administered intracolonically. The animals were sacrificed 3 days later and the extent of colonic necrosis and hyperemia was measured with an image analyzer. The i.p. administration of BPC-15 significantly reduced the extent of TNBS-induced colonic damage in a dose-dependent manner. This was associated with a statistically significant and dose-dependent reduction in colonic tissue MPO activity. At the dose tested (10 nmol/kg), intracolonic administration of BPC-15 did not significantly reduce either the extent of the colonic damage or the increase in MPO activity induced by TNBS. In conclusion, this study showed that i.p. administration of BPC-15 reduced TNBS-induced colonic damage in rats.
Study Information
pubmed
1995